527 related articles for article (PubMed ID: 24919951)
21. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.
Filipović A; Lombardo Y; Faronato M; Abrahams J; Aboagye E; Nguyen QD; d'Aqua BB; Ridley A; Green A; Rahka E; Ellis I; Recchi C; Przulj N; Sarajlić A; Alattia JR; Fraering P; Deonarain M; Coombes RC
Breast Cancer Res Treat; 2014 Nov; 148(2):455-62. PubMed ID: 25248409
[TBL] [Abstract][Full Text] [Related]
22. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
23. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
[TBL] [Abstract][Full Text] [Related]
24. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
25. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
26. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
[TBL] [Abstract][Full Text] [Related]
27. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
28. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
29. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
30. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.
Harrison H; Farnie G; Howell SJ; Rock RE; Stylianou S; Brennan KR; Bundred NJ; Clarke RB
Cancer Res; 2010 Jan; 70(2):709-18. PubMed ID: 20068161
[TBL] [Abstract][Full Text] [Related]
31. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.
Hsu EC; Kulp SK; Huang HL; Tu HJ; Salunke SB; Sullivan NJ; Sun D; Wicha MS; Shapiro CL; Chen CS
Neoplasia; 2015 Jun; 17(6):497-508. PubMed ID: 26152358
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
33. Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma.
Lin X; Sun B; Zhu D; Zhao X; Sun R; Zhang Y; Zhang D; Dong X; Gu Q; Li Y; Liu F
Cancer Sci; 2016 Aug; 107(8):1079-91. PubMed ID: 27234159
[TBL] [Abstract][Full Text] [Related]
34. Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.
Cai J; Sun H; Zheng B; Xie M; Xu C; Zhang G; Huang X; Zhuang J
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179087
[TBL] [Abstract][Full Text] [Related]
35. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
Ward A; Balwierz A; Zhang JD; Küblbeck M; Pawitan Y; Hielscher T; Wiemann S; Sahin Ö
Oncogene; 2013 Feb; 32(9):1173-82. PubMed ID: 22508479
[TBL] [Abstract][Full Text] [Related]
36. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
37. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells.
Petri BJ; Piell KM; South Whitt GC; Wilt AE; Poulton CC; Lehman NL; Clem BF; Nystoriak MA; Wysoczynski M; Klinge CM
Cancer Lett; 2021 Oct; 518():152-168. PubMed ID: 34273466
[TBL] [Abstract][Full Text] [Related]
38. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
39. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
[TBL] [Abstract][Full Text] [Related]
40. Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.
Hu Y; Li S; Yang M; Yan C; Fan D; Zhou Y; Zhang Y; Yagüe E; Xiong D
Breast Cancer Res Treat; 2014 Jan; 143(2):287-99. PubMed ID: 24337682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
